Drugs & Targets NCTN trials clinically meaningful and cost-effective, study finds September 20, 2019Vol.45 No.35
Drugs & Targets Invitae offers no-charge genetic testing to patients with pancreatic cancer September 20, 2019Vol.45 No.35
Clinical Roundup Higher patient volumes associated with longer survival in multiple myeloma September 20, 2019Vol.45 No.35
Clinical Roundup Darzalex shows high response rate, depth of response in multiple myeloma transplant-eligible patients September 20, 2019Vol.45 No.35
Clinical Roundup ‘Scoop’ pathway leads to better health outcomes, lower costs in cancer care September 20, 2019Vol.45 No.35
Clinical Roundup OVA1 shows ovarian malignancy risk detection in African-American women September 20, 2019Vol.45 No.35
Challenges to leveraging real-world evidence for FDA approval September 20, 2019Vol.45 No.35By Ash Malik
In Brief SU2C to spend $6 million on two trials in breast, prostate cancer September 20, 2019Vol.45 No.35
In Brief Broxmeyer receives Cord Blood Association’s Lifetime Achievement Award September 20, 2019Vol.45 No.35
